« Return to News | Awards & Advancement

KJT Group names director of Health Outcomes

Wednesday, July 10, 2013 04:19 PM

KJT Group, a life sciences market research and insight consultancy firm, has named Arun Changolkar, Ph.D., M.B.A., director of Health Outcomes Research,  its life sciences research and consulting organization.

Changolkar brings academic and professional experience in health economics and outcomes research. His experience includes leadership roles in the pharmaceutical and clinical research industries. With expertise in epidemiology and statistics, his project experience spans both U.S. and global healthcare in oncology, vaccines and autoimmune disease.

Previously, he was director of Global Health Outcomes at Stiefel and manager of Health Outcomes and Analytics at GlaxoSmithKline. He designed and executed HEOR studies to support multiple global country specific successful reimbursement submissions, supporting clinical trials and various other post-marketing observational studies to generate clinical evidence. He also participated in and contributed to strategic pricing, global value dossier synthesis and core value development for various pharmaceutical products.

Changolkar will work closely with KJT Group researchers and oversee the design and conduct of KJT Group's health economics and outcomes research studies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.